A first-in-human study of ATV-1601 in patients with AKT1 E17K mutant tumors
Latest Information Update: 17 Oct 2024
At a glance
- Drugs ATV-1601 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man; Proof of concept
- 17 Oct 2024 New trial record
- 15 Oct 2024 According to an Atavistik Bio media release, company anticipates initiating a first-in-human study with ATV-1601 in patients with AKT1 E17K mutant tumors in early 2025.